Arcutis Biotherapeutics, INC Form 4 insider transactions

Larry Todd Edwards, SVP and Chief Commercial Officer of Arcutis Biotherapeutics, sold shares to cover tax obligations following the vesting of restricted stock units.

SVP and Chief Business Officer of Arcutis Biotherapeutics, Matthew Moore, reports acquisition and disposal of common stock related to vesting of Restricted Stock Units.

Arcutis Biotherapeutics CEO Todd Franklin Watanabe sold 13,783 shares of common stock on May 2, 2024, to satisfy tax withholding obligations related to vesting Restricted Stock Units.

Masaru Matsuda, Senior Vice President and General Counsel of Arcutis Biotherapeutics, sold 5,016 shares of common stock on May 2, 2024, to cover tax withholding obligations related to vesting Restricted Stock Units.

Patrick Burnett, Senior Vice President and Chief Medical Officer of Arcutis Biotherapeutics, sold 9,555 shares of common stock on May 2, 2024, to satisfy tax withholding obligations related to vesting Restricted Stock Units.

David Topper, CFO of Arcutis Biotherapeutics, was granted stock options and restricted stock units on April 10, 2024, according to a Form 4 filing with the SEC.

Masaru Matsuda, Senior Vice President and General Counsel of Arcutis Biotherapeutics, sold 3,760 shares of common stock on March 4, 2024, to satisfy tax withholding obligations related to vesting Restricted Stock Units.

Patrick Burnett, Senior Vice President and Chief Medical Officer of Arcutis Biotherapeutics, sold 4,782 shares of common stock on March 4, 2024, to satisfy tax withholding obligations related to vesting Restricted Stock Units.

Arcutis Biotherapeutics CEO Todd Franklin Watanabe sold 14,903 shares of common stock on March 4, 2024, to satisfy tax withholding obligations related to vesting Restricted Stock Units.

Arcutis Biotherapeutics' SVP and Chief Business Officer, Matthew Richard Moore, sold 3,468 shares of common stock on March 4, 2024, to cover tax obligations related to vesting Restricted Stock Units.

Director Patrick J. Heron reports the acquisition of 21,052 shares of Arcutis Biotherapeutics, Inc. common stock at $9.50 per share on March 4, 2024.

Arcutis Biotherapeutics CEO Todd Franklin Watanabe sold 2,465 shares of common stock on February 28, 2024, to satisfy tax withholding obligations related to vesting restricted stock units.